Treatment methods for non-pancreatic gastrointestinal cancers
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- アイオンクチュラ·ベー·フェー
- Filing Date
- 2024-05-31
- Publication Date
- 2026-06-25
Smart Images
Figure 2026520859000001_ABST
Abstract
Claims
1. Compound of formula I for use in the treatment of non-pancreatic gastrointestinal cancers: 【Chemistry 1】 or a pharmaceutically acceptable salt thereof.
2. The compound or salt for use according to claim 1, wherein the non-pancreatic gastrointestinal cancer is selected from liver cancer, bile duct cancer, or colorectal cancer.
3. The compound or salt for use according to claim 1 or claim 2, wherein the non-pancreatic gastrointestinal cancer is liver cancer.
4. The compound or salt for use according to claim 1 or claim 2, wherein the non-pancreatic gastrointestinal cancer is bile duct cancer.
5. The compound or salt for use according to claim 1 or 2, wherein the non-pancreatic gastrointestinal cancer is colorectal cancer.
6. The compound or salt for use according to any one of claims 1 to 5, wherein the compound of formula I is administered in a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, carrier or excipient, the pharmaceutical composition being suitable for oral administration.
7. The compound or salt for use according to any one of claims 1 to 6, wherein the method comprises administering an additional therapeutically effective amount of chemotherapeutic agent.
8. The compound or salt for use according to claim 7, wherein the additional chemotherapeutic agent is selected from gemcitabine, cisplatin, doxorubicin, mitoxantrone, 5-fluorouracil (5-FU), capecitabine, irinotecan, oxaliplatin, trifluridine, and tipiracil.
9. A method for treating non-pancreatic gastrointestinal cancer in a subject requiring treatment for non-pancreatic gastrointestinal cancer, wherein the subject is given a compound of formula I: 【Chemistry 2】 The method comprising administering a pharmaceutically acceptable salt thereof.
10. The method according to claim 9, wherein the non-pancreatic gastrointestinal cancer is selected from liver cancer, bile duct cancer, or colorectal cancer.
11. The method according to claim 9 or claim 10, wherein the non-pancreatic gastrointestinal cancer is liver cancer.
12. The method according to either claim 9 or claim 10, wherein the non-pancreatic gastrointestinal cancer is bile duct cancer.
13. The method according to claim 9 or claim 10, wherein the non-pancreatic gastrointestinal cancer is colorectal cancer.
14. The method according to any one of claims 9 to 13, wherein the compound of formula I is administered in a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, carrier or excipient, the pharmaceutical composition being suitable for oral administration.
15. The method according to any one of claims 9 to 14, wherein the method comprises administering an additional therapeutically effective amount of chemotherapeutic agent.
16. The method according to claim 15, wherein the additional chemotherapeutic agent is selected from gemcitabine, cisplatin, doxorubicin, mitoxantrone, 5-fluorouracil (5-FU), capecitabine, irinotecan, oxaliplatin, trifluridine, and tipiracil.
17. Compounds of formula I in the manufacture of pharmaceuticals for use in the treatment of non-pancreatic gastrointestinal cancers: 【Transformation 3】 or the use of a pharmaceutically acceptable salt thereof.
18. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 17, wherein the non-pancreatic gastrointestinal cancer is selected from liver cancer, bile duct cancer, or colorectal cancer.
19. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 17 or claim 18, wherein the non-pancreatic gastrointestinal cancer is liver cancer.
20. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 17 or claim 18, wherein the non-pancreatic gastrointestinal cancer is bile duct cancer.
21. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 17 or claim 18, wherein the non-pancreatic gastrointestinal cancer is colorectal cancer.
22. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 17 to 21, wherein the compound of formula I is administered in a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, carrier or excipient, and the pharmaceutical composition is suitable for oral administration.
23. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 17 to 22, wherein the method comprises administering an additional therapeutically effective amount of chemotherapeutic agent.
24. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 23, wherein the additional chemotherapeutic agent is selected from gemcitabine, cisplatin, doxorubicin, mitoxantrone, 5-fluorouracil (5-FU), capecitabine, irinotecan, oxaliplatin, trifluridine, and tipiracil.